Evaluation of risk factors for thrombophilia in patients with cerebral venous thrombosis.
OBJECTIVE
The increased risk for thrombosis is known as hypercoagulability or thrombophilia. In our study, we aimed to compare the frequency of the identified defects for thrombophilia in patients with central venous thrombosis and under the age of 50 years, with the findings in the current literature.


METHODS
Forty-three patients (16-50 years old) were retrospectively evaluated. Thrombophilia investigation included determinations of protein C, protein S, antithrombin, and activated protein C resistance, factor V Leiden (FVL), prothrombin 20210A (PT 20210) and methylene tetrahydrofolate reductase (MTHFR) C677T mutations, antiphospholipid antibodies (APA), factor VIII levels, and homocysteine levels.


RESULTS
We detected a single thrombophilic defect in 67.4%, two defects in 27.9% and three defects in 4.7% of our patients. The most common thrombophilic defect was mutation in the MTHFR gene (41.8%), and this was followed by the FVL mutation (34.9%).


CONCLUSIONS
Since the prevalence of individual thrombophilic defects varies in each population, ethnic group and geographical location, screening for thrombophilic defects in patients presenting with cerebral venous thrombosis should primarily investigate the most frequent thrombophilia risk factors.
Osman
O
Yokuş
Dizgi Sok. 9/6 Basınevleri, 06120 Ankara, Turkey Phone: +90 312 321 66 97 E-mail: drozlembalcik@yahoo.com.
Özlem
Ö
Şahin Balçık
Murat
M
Albayrak
Funda
F
Ceran
Simten
S
Dağdaş
Mesude
M
Yılmaz
Gülsüm
G
Özet